- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SmartLight to introduce new viewer at RSNA
Israeli computerized light box developer SmartLight plans to introduce a new, mid-level motorized viewer at the upcoming RSNA show. The company’s SL8000 SLX Smart Motorized Viewer carries all of SmartLight’s motorized viewer technology and is
Israeli computerized light box developer SmartLight plans to introduce a new, mid-level motorized viewer at the upcoming RSNA show. The companys SL8000 SLX Smart Motorized Viewer carries all of SmartLights motorized viewer technology and is ticketed at a reasonable price, according to Robert Sohval, Ph.D., chairman of SmartLight. The unit can be configured with Smartlights Archive Wizard technology, a function that enables viewers to control the storage and display of images, and can be upgraded with MamPac, a mammography screening package, and ID Master, a feature giving radiologists access to their own cases with the push of a button. The Haifa, Israel-based firm received clearance from the Food and Drug Administration for its first two motorized viewers, SL8000 and SL8000 DLX, in 1997 (SCAN 1/21/98).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
